Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
2015; Elsevier BV; Volume: 126; Issue: 20 Linguagem: Inglês
10.1182/blood-2015-05-643320
ISSN1528-0020
AutoresJatin J. Shah, Edward A. Stadtmauer, Rafat Abonour, Adam D. Cohen, William Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Christina L. Gomes, N G Pascucci, David Smith, Robert Z. Orlowski, Brian G.M. Durie,
Tópico(s)Peptidase Inhibition and Analysis
ResumoKey Points This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
Referência(s)